Loading
Duboce Biopharmaceuticals is developing DBC-664, an antibody that links the immune system's T cells to cancer cells carrying the proteins ALPP or ALPPL2, which are common in ovarian and endometrial cancers. It is in a first human trial.
Duboce Biopharmaceuticals, Inc. is a single-asset portfolio company of TCG Labs Soleil, the South San Francisco venture-biotech organisation formed with The Column Group. Its candidate DBC-664 is an ALPP/ALPPL2 x CD3 T-cell engager directed at antigens highly expressed, most homogeneously, in ovarian and endometrial cancers. A first-in-human, open-label, multicentre phase 1a/1b study (NCT07705035) in adults with relapsed or refractory, unresectable locally advanced or metastatic solid tumours associated with ALPP or ALPPL2 expression, including germ cell tumours, lung, gastric and oesophageal, urothelial, endometrial and ovarian adenocarcinomas, began recruiting in 2026. Its first registered cancer trial, NCT07705035, was posted on ClinicalTrials.gov in July 2026.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
Shares Bispecific antibodies, T-cell engagers (bispecific), Ovarian cancer.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific), Ovarian cancer.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific), Ovarian cancer.
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/